Chiara Riganti

Summary

Affiliation: University of Turin
Country: Italy

Publications

  1. Salaroglio I, Mujumdar P, Annovazzi L, Kopecka J, Mellai M, Schiffer D, et al. Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma. Mol Cancer Ther. 2018;17:2598-2609 pubmed publisher
    ..This novel mechanism of action, via the interaction of CAXII and Pgp, ultimately blocks the efflux function of Pgp to improve glioblastoma patient outcomes. ..
  2. Muntoni E, Martina K, Marini E, Giorgis M, Lazzarato L, Salaroglio I, et al. Methotrexate-Loaded Solid Lipid Nanoparticles: Protein Functionalization to Improve Brain Biodistribution. Pharmaceutics. 2019;11: pubmed publisher
    ..This is probably because this method provided improved ligand⁻receptor interactions and selectivity for the target tissue. ..
  3. Salaroglio I, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd Elrahman G, et al. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. J Exp Clin Cancer Res. 2018;37:286 pubmed publisher
    ..Lysosome and proteasome inhibitors associated with doxorubicin may overcome the resistance to the drug in TNBC. ..
  4. Buondonno I, Gazzano E, Tavanti E, Chegaev K, Kopecka J, Fanelli M, et al. Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. Cell Mol Life Sci. 2019;76:609-625 pubmed publisher
    ..Sdox may represent the prototype of innovative anthracyclines, effective against doxorubicin-resistant/Pgp-expressing osteosarcoma cells by perturbing the ER functions. ..
  5. Kopecka J, Salaroglio I, Righi L, Libener R, Orecchia S, Grosso F, et al. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma. Lung Cancer. 2018;120:34-45 pubmed publisher
    ..The association of proteasome and lysosome inhibitors reverses cisplatin resistance by restoring LIP levels and may represent a new adjuvant strategy in MPM treatment. ..
  6. Riganti C, Salaroglio I, Caldera V, Campia I, Kopecka J, Mellai M, et al. Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/?-catenin pathway. Neuro Oncol. 2013;15:1502-17 pubmed publisher
    ..Our work suggests that Wnt3a is an autocrine mediator of stemness, proliferation, and chemoresistance in human glioblastoma and that temozolomide may chemosensitize the stem cell population by downregulating Wnt3a signaling. ..
  7. request reprint
    Riganti C, Campia I, Kopecka J, Gazzano E, Doublier S, Aldieri E, et al. Pleiotropic effects of cardioactive glycosides. Curr Med Chem. 2011;18:872-85 pubmed
  8. Salaroglio I, Gazzano E, Kopecka J, Chegaev K, Costamagna C, Fruttero R, et al. New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro. Molecules. 2018;23: pubmed publisher
    ..Our work identified new ligands of Pgp active at low nanomolar concentrations. These compounds reduce Pgp activity in BBB and GB and improve in vitro chemotherapy efficacy in this tumor. ..
  9. Corsetto P, Colombo I, Kopecka J, Rizzo A, Riganti C. ?-3 Long Chain Polyunsaturated Fatty Acids as Sensitizing Agents and Multidrug Resistance Revertants in Cancer Therapy. Int J Mol Sci. 2017;18: pubmed publisher
    ..Of note, ?-3 LCPUFAs often alter the lipid compositions more in chemoresistant cells than in chemosensitive cells, suggesting a potential adjuvant role in the treatment of drug resistant cancers. ..

More Information

Publications17

  1. Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, et al. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS ONE. 2013;8:e60975 pubmed publisher
    ..These data indicate that MDR+ cells have an hyper-active mevalonate pathway which is targetable with zoledronic acid to antagonize their ability to withstand chemotherapy-induced cytotoxicity and escape immunogenic cell death. ..
  2. request reprint
    Buondonno I, Gazzano E, Jean S, Audrito V, Kopecka J, Fanelli M, et al. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. Mol Cancer Ther. 2016;15:2640-2652 pubmed
    ..Mol Cancer Ther; 15(11); 2640-52. ©2016 AACR. ..
  3. Salaroglio I, Panada E, Moiso E, Buondonno I, Provero P, Rubinstein M, et al. PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. Mol Cancer. 2017;16:91 pubmed publisher
    ..The PERK/Nrf2/MRP1 axis is responsible for the resistance to ER stress and chemotherapy, and may represent a good therapeutic target in aggressive and resistant tumors. ..
  4. Gazzano E, Rolando B, Chegaev K, Salaroglio I, Kopecka J, Pedrini I, et al. Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. J Control Release. 2018;270:37-52 pubmed publisher
  5. Gazzano E, Chegaev K, Rolando B, Blangetti M, Annaratone L, Ghigo D, et al. Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. Bioorg Med Chem. 2016;24:967-75 pubmed publisher
    ..Only compounds with high mitochondria retention (due to nitration of mitochondrial efflux transporter) exert high cytotoxicity, through the activation of a mitochondrial-dependent apoptosis. ..
  6. request reprint
    Pinzón Daza M, Campia I, Kopecka J, Garzón R, Ghigo D, Riganti C. Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier. Curr Drug Metab. 2013;14:625-40 pubmed
  7. Riganti C, Pinto H, Bolli E, Belisario D, Calogero R, Bosia A, et al. Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer. Biochem Pharmacol. 2011;82:1079-89 pubmed publisher
    ..The latter event dissipates the antitumor efficacy that may arise from the former one. Only the association of statins and NF-?B-targeted therapies efficiently decreased proliferation of tumor cells. ..
  8. Riganti C, Costamagna C, Doublier S, Miraglia E, Polimeni M, Bosia A, et al. The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress. Toxicol Appl Pharmacol. 2008;228:277-85 pubmed publisher